FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379802644> ?p ?o ?g. }

• W4379802644 endingPage "1625" @default.
• W4379802644 startingPage "1624.2" @default.
• W4379802644 abstract "Background In systemic sclerosis (SSc), the role of oral anticoagulants (OACs) for treating or preventing the occurrence of digital ulcers (DUs) is not well understood. Given the low prevalence of OACs used in these patients, standard frequentist statistics are not suitable to capture the effect of OACs on DUs conclusively. However, a Bayesian statistical approach, which incorporates prior knowledge, can deal with a low prevalence of outcome or exposure and might provide conclusive evidence. Objectives To assess the effectiveness of a therapy with OACs on DUs in patients with SSc. Methods This study used prospectively collected data from the European Scleroderma Trials and Research group (EUSTAR) registry. Patients fulfilling the 2013 ACR/EULAR SSc classification criteria with complete longitudinal data on the presence of DUs and OACs were included in the analysis. The Bayesian prior probability distribution was created by capturing SSc experts’ opinion on the probability of absence of DUs with and without OACs and their degree of uncertainty using a questionnaire. In addition, participants ranked factors that influence the presence or absence of DUs as confounding factors using a numeric rating scale. The outcome was the absence of DUs at the last follow-up visit in SSc patients from the EUSTAR cohort, after one year of exposure to OAC. A nearest neighbor matching algorithm using Bayesian Additive Regression Trees with uniform priors generated a cohort with two groups of patients (treated and non-treated with OACs), which were balanced for age, sex, anti-Scl-70 antibody positivity, joint contractures, use of platelet inhibitors, use of prostacyclin analogues, use of any endothelin receptors antagonists or any phosphodiesterase type 5 inhibitor. The matching algorithm generated two balanced groups of treated and untreated patients (imbalance < 10%). A Bayesian logistic regression was implemented to estimate the effect of OACs on DUs. This model incorporated the priors elicited from experts’ beliefs and was adjusted for the above mentioned factors that influence the absence of DUs, as well as modified Rodnan skin score, disease duration, season, left ventricular ejection fraction, presence of pulmonary hypertension, C-reactive protein elevation, arterial hypertension and any previous DUs. Results Of the 6,424 patients enrolled in the EUSTAR registry, 663 (10.3%) had current digital ulcers, 2556 (39.8%) had previous DUs and 143 (2.2%) were exposed to OACs at their last follow-up visit. Mean age was 59 (SD: 13.6) years, 933 (14.5%) were males, mean disease duration was 13.1 (SD: 8.7) years, 4,454 (69.3%) had a limited cutaneous SSc and 1510 (23.5%) had C-reactive protein elevation. The median probability for the absence of DUs after exposure of one year to OACs was 70-75%, the pessimistic and optimistic probability were 70-75% and 80-85% respectively. After incorporation of the prior experts’ opinion, the unadjusted analysis revealed that the use of OACs was associated with absence of DUs at the last follow-up visit (OR 2.05, 95%CrI 1.63 to 2.46). In the adjusted analysis, the effect is OACs was slightly stronger (OR 2.15, 95%CrI, 1.71 to 2.52). The results of the analysis where the priors from experts were withheld (and uniform priors were set) are illustrated in figure 1. Conclusion This study indicates with incorporation of Bayesian priors that represent experts’ beliefs, a positive effect of OACs for the DUs in SSc. Figure 1. Effect of OACs on the absence DUs related to SSc at the last follow-up visit. Bayesian (priors): Analysis where the prior knowledge from the experts was incorporated into the model. Bayesian (uniform): Analysis where the prior knowledge from the experts was not incorporated into the model and a uniform/uninformative/neutral prior was used. OACs: Oral anticoagulants. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests Alexandru Garaiman: None declared, Catherine Gebhard: None declared, Carina Mihai Consultant of: Consulting fees and/or honoraria from Boehringer Ingelheim, Janssen, MED Talks Switzerland, Mepha, and PlayToKnow AG and consulting fees and/or honoraria from Boehringer Ingelheim, Janssen, MED Talks Switzerland, Mepha, and PlayToKnow AG, outside the submitted work, Rucsandra Dobrota Consultant of: consulting or speaker fees from Actelion and Boehringer-Ingelheim, congress support from Amgen, outside the submitted work, Grant/research support from: research grants from Articulum Fellowship, sponsored by Pfizer (2013-2014), Actelion, outside the submitted work, Cosimo Bruni Speakers bureau: Eli-Lilly, Consultant of: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Grant/research support from: Gruppo Italiano Lotta alla Sclerodermia (GILS), European Scleroderma Trials and Research Group (EUSTAR), Foundation for research in Rheumatology (FOREUM), Scleroderma Clinical Trials Consortium (SCTC). Educational grants from AbbVie., Marco Matucci-Cerinic: None declared, Jörg Henes Consultant of: Abbvie, Boehringer Ingelheim, GSK, BMS, Janssen, Novartis, Pfizer, UCB, Jeska de Vries-Bouwstra Consultant of: ABBvie, Janssen, Boehringer-Ingerlheim, Grant/research support from: Janssen-Cilag, Galapagos, Roche, Vanessa Smith: None declared, Andrea Doria: None declared, Yannick Allanore Consultant of: AbbVie, AstraZeneca, Bayer, Boehringer-Ingelheim, Mylan, Janssen, Medsenic, Prometheus, Sanofi, Roche, Grant/research support from: Alpine Immunosciences, Medsenic, OSE Immunotherapeutics, Lorenzo Dagna: None declared, Branimir Anic: None declared, Carlomaurizio Montecucco: None declared, Otylia Kowal-Bielecka Consultant of: Abbvie, Boehringer Ingelheim, CSL Behring, Janssen, Medac, MSD, Novartis, Pfizer, Sandoz, Mickael Martin: None declared, Yoshiya Tanaka Speakers bureau: Behringer-Ingelheim, Eli Lilly, Abbvie, Gilead, AstraZeneca, Bristol-Myers, Chugai, Daiichi-Sankyo, Eisai, Pfizer, Mitsubishi-Tanabe, GlaxoSmithKline, Grant/research support from: Asahi-Kasei, Abbvie, Chugai, Eisai, Takeda, Daiichi-Sankyo, Behringer-Ingelheim., Anna-Maria Hoffmann-Vold Speakers bureau: Boehringer Ingelheim, Jannsen, Medscape, Merck Sharp & Dohme and Roche, Consultant of: ARXX, Boehringer Ingelheim, Genentech, Jannsen, Medscape, Merck Sharp & Dohme and Roche, Grant/research support from: Boehringer Ingelheim, Jannsen, Oliver Distler Speakers bureau: Bayer, Boehringer Ingelheim, Janssen, Medscape, Consultant of: Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur, Grant/research support from: Kymera, Mitsubishi Tanabe, Boehringer Ingelheim, Mike O. Becker Speakers bureau: Mepha, Bayer, MSD, GSK, Amgen, Novartis and Vifor, Consultant of: Mepha, Bayer, MSD, GSK, Amgen, Novartis and Vifor." @default.
• W4379802644 created "2023-06-09" @default.
• W4379802644 creator A5003089499 @default.
• W4379802644 creator A5005416361 @default.
• W4379802644 creator A5012973190 @default.
• W4379802644 creator A5015953107 @default.
• W4379802644 creator A5018529897 @default.
• W4379802644 creator A5026345780 @default.
• W4379802644 creator A5027512145 @default.
• W4379802644 creator A5028304403 @default.
• W4379802644 creator A5039032334 @default.
• W4379802644 creator A5042709055 @default.
• W4379802644 creator A5042834007 @default.
• W4379802644 creator A5048430823 @default.
• W4379802644 creator A5053890524 @default.
• W4379802644 creator A5057564195 @default.
• W4379802644 creator A5064215282 @default.
• W4379802644 creator A5072353591 @default.
• W4379802644 creator A5075122822 @default.
• W4379802644 creator A5080777335 @default.
• W4379802644 creator A5084426712 @default.
• W4379802644 creator A5089645830 @default.
• W4379802644 date "2023-05-30" @default.
• W4379802644 modified "2023-10-18" @default.
• W4379802644 title "AB0823 A BAYESIAN APPROACH TO DETERMINE THE ROLE OF ORAL ANTICOAGULANTS FOR THE OCCURRENCE OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS – A EUSTAR OBSERVATIONAL STUDY" @default.
• W4379802644 doi "https://doi.org/10.1136/annrheumdis-2023-eular.3915" @default.
• W4379802644 hasPublicationYear "2023" @default.
• W4379802644 type Work @default.
• W4379802644 citedByCount "0" @default.
• W4379802644 crossrefType "journal-article" @default.
• W4379802644 hasAuthorship W4379802644A5003089499 @default.
• W4379802644 hasAuthorship W4379802644A5005416361 @default.
• W4379802644 hasAuthorship W4379802644A5012973190 @default.
• W4379802644 hasAuthorship W4379802644A5015953107 @default.
• W4379802644 hasAuthorship W4379802644A5018529897 @default.
• W4379802644 hasAuthorship W4379802644A5026345780 @default.
• W4379802644 hasAuthorship W4379802644A5027512145 @default.
• W4379802644 hasAuthorship W4379802644A5028304403 @default.
• W4379802644 hasAuthorship W4379802644A5039032334 @default.
• W4379802644 hasAuthorship W4379802644A5042709055 @default.
• W4379802644 hasAuthorship W4379802644A5042834007 @default.
• W4379802644 hasAuthorship W4379802644A5048430823 @default.
• W4379802644 hasAuthorship W4379802644A5053890524 @default.
• W4379802644 hasAuthorship W4379802644A5057564195 @default.
• W4379802644 hasAuthorship W4379802644A5064215282 @default.
• W4379802644 hasAuthorship W4379802644A5072353591 @default.
• W4379802644 hasAuthorship W4379802644A5075122822 @default.
• W4379802644 hasAuthorship W4379802644A5080777335 @default.
• W4379802644 hasAuthorship W4379802644A5084426712 @default.
• W4379802644 hasAuthorship W4379802644A5089645830 @default.
• W4379802644 hasBestOaLocation W43798026441 @default.
• W4379802644 hasConcept C105795698 @default.
• W4379802644 hasConcept C107673813 @default.
• W4379802644 hasConcept C126322002 @default.
• W4379802644 hasConcept C160234255 @default.
• W4379802644 hasConcept C162376815 @default.
• W4379802644 hasConcept C1862650 @default.
• W4379802644 hasConcept C23131810 @default.
• W4379802644 hasConcept C33923547 @default.
• W4379802644 hasConcept C71924100 @default.
• W4379802644 hasConcept C72563966 @default.
• W4379802644 hasConcept C77350462 @default.
• W4379802644 hasConceptScore W4379802644C105795698 @default.
• W4379802644 hasConceptScore W4379802644C107673813 @default.
• W4379802644 hasConceptScore W4379802644C126322002 @default.
• W4379802644 hasConceptScore W4379802644C160234255 @default.
• W4379802644 hasConceptScore W4379802644C162376815 @default.
• W4379802644 hasConceptScore W4379802644C1862650 @default.
• W4379802644 hasConceptScore W4379802644C23131810 @default.
• W4379802644 hasConceptScore W4379802644C33923547 @default.
• W4379802644 hasConceptScore W4379802644C71924100 @default.
• W4379802644 hasConceptScore W4379802644C72563966 @default.
• W4379802644 hasConceptScore W4379802644C77350462 @default.
• W4379802644 hasIssue "Suppl 1" @default.
• W4379802644 hasLocation W43798026441 @default.
• W4379802644 hasOpenAccess W4379802644 @default.
• W4379802644 hasPrimaryLocation W43798026441 @default.
• W4379802644 hasRelatedWork W1975046232 @default.
• W4379802644 hasRelatedWork W2087578045 @default.
• W4379802644 hasRelatedWork W2166247085 @default.
• W4379802644 hasRelatedWork W2187151507 @default.
• W4379802644 hasRelatedWork W2313076522 @default.
• W4379802644 hasRelatedWork W2788293168 @default.
• W4379802644 hasRelatedWork W2945412111 @default.
• W4379802644 hasRelatedWork W2999178879 @default.
• W4379802644 hasRelatedWork W3211486482 @default.
• W4379802644 hasRelatedWork W2103615397 @default.
• W4379802644 hasVolume "82" @default.
• W4379802644 isParatext "false" @default.
• W4379802644 isRetracted "false" @default.
• W4379802644 workType "article" @default.